DK1222171T3 - Pyridiniumderivater, til regulering af aldersrelaterede og diabetesvaskulære komplikationer, fremgangsmåde til fremstilling af disse samt terapeutiske anvendelser deraf - Google Patents

Pyridiniumderivater, til regulering af aldersrelaterede og diabetesvaskulære komplikationer, fremgangsmåde til fremstilling af disse samt terapeutiske anvendelser deraf

Info

Publication number: DK1222171T3
Authority: DK; Denmark
Prior art keywords: nhr; heteroaryl; aryl; age; alkyl
Prior art date: 1999-10-06

Application number

DK99973986T

Other languages

Danish (da)

English (en)

Inventor

Alangudi Sankaranarayanan

Original Assignee

Torrent Pharmaceuticals Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-10-06

Filing date

1999-10-15

Publication date

2004-07-05

1999-10-15 Application filed by Torrent Pharmaceuticals Ltd filed Critical Torrent Pharmaceuticals Ltd

2004-07-05 Application granted granted Critical

2004-07-05 Publication of DK1222171T3 publication Critical patent/DK1222171T3/da

Links

JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical class C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 title abstract 3
238000000034 method Methods 0.000 title abstract 3
201000009101 diabetic angiopathy Diseases 0.000 title 1
230000001225 therapeutic effect Effects 0.000 title 1
108010005094 Advanced Glycation End Products Proteins 0.000 abstract 5
125000001072 heteroaryl group Chemical group 0.000 abstract 5
125000000217 alkyl group Chemical group 0.000 abstract 4
125000003118 aryl group Chemical group 0.000 abstract 4
101100516568 Caenorhabditis elegans nhr-7 gene Proteins 0.000 abstract 3
230000000694 effects Effects 0.000 abstract 3
101150009274 nhr-1 gene Proteins 0.000 abstract 3
OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 abstract 2
PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 abstract 2
239000003814 drug Substances 0.000 abstract 2
239000002953 phosphate buffered saline Substances 0.000 abstract 2
150000003839 salts Chemical class 0.000 abstract 2
239000000243 solution Substances 0.000 abstract 2
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 abstract 1
NJQFCQXFOHVYQJ-PMACEKPBSA-N BF 4 Chemical compound C1([C@@H]2CC(=O)C=3C(O)=C(C)C4=C(C=3O2)[C@H](C(C)C)C2=C(O4)C(C)=C(C(C2=O)(C)C)OC)=CC=CC=C1 NJQFCQXFOHVYQJ-PMACEKPBSA-N 0.000 abstract 1
108091003079 Bovine Serum Albumin Proteins 0.000 abstract 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 abstract 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 abstract 1
208000002249 Diabetes Complications Diseases 0.000 abstract 1
206010012655 Diabetic complications Diseases 0.000 abstract 1
206010048554 Endothelial dysfunction Diseases 0.000 abstract 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 abstract 1
208000028389 Nerve injury Diseases 0.000 abstract 1
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 abstract 1
229910019142 PO4 Inorganic materials 0.000 abstract 1
ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 abstract 1
208000017442 Retinal disease Diseases 0.000 abstract 1
206010038923 Retinopathy Diseases 0.000 abstract 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 abstract 1
LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 abstract 1
125000002252 acyl group Chemical group 0.000 abstract 1
230000032683 aging Effects 0.000 abstract 1
230000003178 anti-diabetic effect Effects 0.000 abstract 1
239000003472 antidiabetic agent Substances 0.000 abstract 1
229940098773 bovine serum albumin Drugs 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
125000000753 cycloalkyl group Chemical group 0.000 abstract 1
206010012601 diabetes mellitus Diseases 0.000 abstract 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 abstract 1
238000002845 discoloration Methods 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
229940079593 drug Drugs 0.000 abstract 1
230000008694 endothelial dysfunction Effects 0.000 abstract 1
230000002431 foraging effect Effects 0.000 abstract 1
125000002485 formyl group Chemical group [H]C(*)=O 0.000 abstract 1
239000008103 glucose Substances 0.000 abstract 1
150000004820 halides Chemical class 0.000 abstract 1
230000005764 inhibitory process Effects 0.000 abstract 1
208000017169 kidney disease Diseases 0.000 abstract 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 abstract 1
238000004519 manufacturing process Methods 0.000 abstract 1
230000010534 mechanism of action Effects 0.000 abstract 1
206010062198 microangiopathy Diseases 0.000 abstract 1
230000008764 nerve damage Effects 0.000 abstract 1
230000000324 neuroprotective effect Effects 0.000 abstract 1
230000004768 organ dysfunction Effects 0.000 abstract 1
VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Inorganic materials [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 abstract 1
VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 abstract 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 abstract 1
239000010452 phosphate Substances 0.000 abstract 1
150000003222 pyridines Chemical class 0.000 abstract 1
JUJWROOIHBZHMG-UHFFFAOYSA-O pyridinium Chemical compound C1=CC=[NH+]C=C1 JUJWROOIHBZHMG-UHFFFAOYSA-O 0.000 abstract 1
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 abstract 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/76—Nitrogen atoms to which a second hetero atom is attached
- C07D213/77—Hydrazine radicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/86—Hydrazides; Thio or imino analogues thereof
- C07D213/87—Hydrazides; Thio or imino analogues thereof in position 3
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Cardiology (AREA)
Urology & Nephrology (AREA)
Heart & Thoracic Surgery (AREA)
Immunology (AREA)
Dermatology (AREA)
Obesity (AREA)
Endocrinology (AREA)
Vascular Medicine (AREA)
Ophthalmology & Optometry (AREA)
Emergency Medicine (AREA)
Hematology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Pyridine Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicinal Preparation (AREA)
Cosmetics (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Hydrogenated Pyridines (AREA)

DK99973986T 1999-10-06 1999-10-15 Pyridiniumderivater, til regulering af aldersrelaterede og diabetesvaskulære komplikationer, fremgangsmåde til fremstilling af disse samt terapeutiske anvendelser deraf DK1222171T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
IN828CA1999		1999-10-06
PCT/IB1999/001683 WO2001025208A1 (en)	1999-10-06	1999-10-15	Pyridinium derivatives for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof

Publications (1)

Publication Number	Publication Date
DK1222171T3 true DK1222171T3 (da)	2004-07-05

Family

ID=11084928

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK99973986T DK1222171T3 (da)	1999-10-06	1999-10-15	Pyridiniumderivater, til regulering af aldersrelaterede og diabetesvaskulære komplikationer, fremgangsmåde til fremstilling af disse samt terapeutiske anvendelser deraf

Country Status (19)

Country	Link
US (2)	US6462057B1 (de)
EP (1)	EP1222171B1 (de)
JP (1)	JP4068843B2 (de)
CN (1)	CN100355731C (de)
AT (1)	ATE260256T1 (de)
AU (1)	AU769940B2 (de)
BR (1)	BRPI9913746F8 (de)
CA (1)	CA2344144C (de)
CZ (1)	CZ291789B6 (de)
DE (1)	DE69915143T2 (de)
DK (1)	DK1222171T3 (de)
ES (1)	ES2216644T3 (de)
HK (1)	HK1044335B (de)
HU (1)	HU227523B1 (de)
MX (1)	MXPA02003495A (de)
PL (1)	PL211112B1 (de)
PT (1)	PT1222171E (de)
RU (1)	RU2215000C2 (de)
WO (1)	WO2001025208A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20020103228A1 (en) *	1999-10-06	2002-08-01	Torrent Pharmaceuticals Ltd.	Composition and method for use of pyridinium derivatives in cosmetic and therapeutic applications
RU2215000C2 (ru) *	1999-10-06	2003-10-27	Торрент Фармасьютикалз Лтд.	Производные солей пиридиния, способ их получения, фармацевтические композиции на их основе и способы лечения
MXPA03005954A (es) *	2000-12-29	2004-05-24	Alteon Inc	Metodo para tratar enfermedades fibroticas u otras indicaciones iiic.
DK1243581T3 (da) *	2001-03-21	2005-10-31	Torrent Pharmaceuticals Ltd	Pyridiniumforbindelser til behandling af AGE-relaterede sygdomme
CZ303214B6 (cs) *	2001-03-21	2012-05-30	Torrent Pharmaceuticals Ltd	Pyridiniová sloucenina, zpusob její výroby, její použití, farmaceutický prostredek ji obsahující, zpusob jeho výroby a jeho použití
CN1259316C (zh) *	2001-04-05	2006-06-14	托伦脱药品有限公司	用于老龄相关性和糖尿病性血管系统并发症的杂环类化合物
WO2003032969A2 (en) *	2001-10-15	2003-04-24	National Research Council Of Canada	Anti-glycation agents for preventing age-, diabetes-, and smoking-related complications
HUP0104831A2 (hu) *	2001-10-19	2003-08-28	Torrent Pharmaceuticals Ltd.	Készítmény és eljárás piridíniumszármazékok gyógyászati alkalmazására
EP1742630A4 (de) *	2004-04-16	2010-01-20	Santarus Inc	Kombination aus protonenpumpenhemmer, puffermittel und prokinetischem wirkstoff
WO2006002983A1 (en) *	2004-07-06	2006-01-12	Novartis Ag	Combination of organic compounds
US20090088433A1 (en) *	2005-01-26	2009-04-02	Bertrand Leblond	Methods of using as analgesics 1-benzyl-1-hydroxy-2,3-diamino-propyl amines, 3-benzyl-3-hydroxy-2-amino-propionic acid amides and related compounds
EP2068841B1 (de)	2006-10-05	2018-09-26	Santarus, Inc.	Neuartige formulierungen von protonenpumpenhemmern und verfahren zu ihrer verwendung
CA2667682A1 (en)	2006-10-27	2008-05-15	The Curators Of The University Of Missouri	Compositions comprising acid labile proton pump inhibiting agents, at least one other pharmaceutically active agent and methods of using same
EP2254563A2 (de)	2008-01-25	2010-12-01	Torrent Pharmaceuticals Ltd.	Pharmazeutische kombinationen mit spezifizierten age-breakern und weiteren arzneimitteln, unter anderem antihypertensiva, antidiabetika usw.
US20120058105A1 (en)	2008-06-27	2012-03-08	Martin Kean Chong Ng	Method of treatment of vascular complications
CN102459175A (zh)	2009-05-07	2012-05-16	托蓝特医药公司	用于治疗糖尿病的哌啶衍生物
UA120389C2 (uk)	2015-04-08	2019-11-25	Торрент Фармасьютікалз Лімітед	Нові сполуки піридинію
LT3280447T (lt) *	2015-04-08	2019-05-27	Torrent Pharmaceuticals Limited	Farmacinės kompozicijos
US11878958B2 (en)	2022-05-25	2024-01-23	Ikena Oncology, Inc.	MEK inhibitors and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CH335521A (de) *	1955-06-02	1959-01-15	Cilag Ag	Verfahren zur Herstellung neuer quaternärer Salze
US4758583A (en)	1984-03-19	1988-07-19	The Rockefeller University	Method and agents for inhibiting protein aging
US5272176A (en)	1984-03-19	1993-12-21	The Rockefeller University	Advanced glycation inhibitors containing amino-benzoic acids and derivatives, and methods of use
US5137916A (en)	1985-11-14	1992-08-11	The Rockefeller University	Advanced glycation inhibitors containing amino-benzoic acids and derivatives, and methods of use
JPH0253759A (ja) *	1988-08-18	1990-02-22	Hamari Yakuhin Kogyo Kk	新規な４級アンモニウム化合物
JPH05216151A (ja) *	1992-02-06	1993-08-27	Konica Corp	ハロゲン化銀写真感光材料
DE69629176T2 (de) *	1995-01-18	2004-06-03	Alteon Inc.	Verwendung von thiazoliumverbindungen zum verhindern und umkehren der bildung von endprodukten der fortgeschrittenen glykosylierung
US5656261A (en)	1995-01-18	1997-08-12	The Picower Institute For Medical Research	Preventing and reversing advanced glycosylation endproducts
CA2285556A1 (en) *	1997-04-04	1998-10-15	Smithkline Beecham Corporation	Calcilytic compounds
RU2215000C2 (ru) *	1999-10-06	2003-10-27	Торрент Фармасьютикалз Лтд.	Производные солей пиридиния, способ их получения, фармацевтические композиции на их основе и способы лечения

1999
- 1999-10-15 RU RU2001107007/04A patent/RU2215000C2/ru active
- 1999-10-15 PT PT99973986T patent/PT1222171E/pt unknown
- 1999-10-15 DE DE69915143T patent/DE69915143T2/de not_active Expired - Lifetime
- 1999-10-15 JP JP2001528154A patent/JP4068843B2/ja not_active Expired - Lifetime
- 1999-10-15 AT AT99973986T patent/ATE260256T1/de active
- 1999-10-15 CN CNB998110388A patent/CN100355731C/zh not_active Expired - Fee Related
- 1999-10-15 HK HK02105889.1A patent/HK1044335B/en not_active IP Right Cessation
- 1999-10-15 CZ CZ20011033A patent/CZ291789B6/cs not_active IP Right Cessation
- 1999-10-15 CA CA002344144A patent/CA2344144C/en not_active Expired - Fee Related
- 1999-10-15 HU HU0104116A patent/HU227523B1/hu unknown
- 1999-10-15 EP EP99973986A patent/EP1222171B1/de not_active Expired - Lifetime
- 1999-10-15 AU AU59942/99A patent/AU769940B2/en not_active Ceased
- 1999-10-15 BR BRC19913746A patent/BRPI9913746F8/pt not_active IP Right Cessation
- 1999-10-15 WO PCT/IB1999/001683 patent/WO2001025208A1/en not_active Ceased
- 1999-10-15 DK DK99973986T patent/DK1222171T3/da active
- 1999-10-15 ES ES99973986T patent/ES2216644T3/es not_active Expired - Lifetime
- 1999-10-15 PL PL348327A patent/PL211112B1/pl unknown
- 1999-10-15 MX MXPA02003495A patent/MXPA02003495A/es active IP Right Grant
2000
- 2000-06-21 US US09/598,410 patent/US6462057B1/en not_active Expired - Lifetime
2002
- 2002-08-09 US US10/214,704 patent/US6624178B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
US20030092744A1 (en)	2003-05-15
WO2001025208A1 (en)	2001-04-12
CZ20011033A3 (cs)	2001-08-15
BR9913746A (pt)	2002-04-23
ATE260256T1 (de)	2004-03-15
PT1222171E (pt)	2004-07-30
HK1044335B (en)	2004-09-10
RU2215000C2 (ru)	2003-10-27
US6462057B1 (en)	2002-10-08
EP1222171A1 (de)	2002-07-17
AU769940B2 (en)	2004-02-12
BR9913746C1 (pt)	2002-08-13
PL348327A1 (en)	2002-05-20
US6624178B2 (en)	2003-09-23
AU5994299A (en)	2001-05-10
HUP0104116A3 (en)	2002-04-29
DE69915143D1 (de)	2004-04-01
BRPI9913746F8 (pt)	2022-01-18
BR9913746F8 (pt)	2021-11-30
MXPA02003495A (es)	2004-04-05
HUP0104116A2 (hu)	2002-03-28
CN100355731C (zh)	2007-12-19
ES2216644T3 (es)	2004-10-16
BR9913746B1 (pt)	2013-03-19
CZ291789B6 (cs)	2003-05-14
BRPI9913746B8 (pt)	2021-05-25
CA2344144C (en)	2008-12-02
EP1222171B1 (de)	2004-02-25
JP2003511369A (ja)	2003-03-25
PL211112B1 (pl)	2012-04-30
CN1318056A (zh)	2001-10-17
DE69915143T2 (de)	2004-10-14
HU227523B1 (en)	2011-07-28
BR9913746F1 (pt)	2020-07-07
JP4068843B2 (ja)	2008-03-26
HK1044335A1 (en)	2002-10-18
CA2344144A1 (en)	2001-04-12
BR9913746E8 (pt)	2018-05-02

Publication	Publication Date	Title
DK1222171T3 (da)	2004-07-05	Pyridiniumderivater, til regulering af aldersrelaterede og diabetesvaskulære komplikationer, fremgangsmåde til fremstilling af disse samt terapeutiske anvendelser deraf
ZA200306370B (en)	2004-06-07	Heterocyclic compounds for aging-related and diabetic vascular complications.
BR112013020424A2 (pt)	2021-04-13	Nitrocatecol substituído, utilizações do mesmo, combinação e composição que o compreendem
US5965615A (en)	1999-10-12	Hydroxyl radical scavenger
RU2001107007A (ru)	2003-04-20	Производные пиридиния для лечения связанных с возрастом и диабетических сосудистых осложнений, способ их получения и их терапевтические применения
CA2714601A1 (en)	2008-09-04	The use of quaternary pyridinium compounds for vasoprotection and/or hepatoprotection
NO20050573L (no)	2005-02-02	4-'7-halo-2-quino (XA) linyloksy ! fenoksypropionsyrederivater som antineoplastiske midler
US20030203877A1 (en)	2003-10-30	Novel post-amadori inhibitors of advanced glycation reactions
ATE6645T1 (de)	1984-03-15	Dibenzoxazepin-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen.
RU2001118854A (ru)	2003-11-20	Оптически активное производное пиридил-4н-1,2,4-оксадиазина и его применение при лечении сосудистых заболеваний
BR9915962A (pt)	2003-01-07	Composto da série do piridìnio, processos para a preparação de composto da série do piridìnio e de uma formulação parenteral, uso de um composto, composição farmacêutica para tratar complicações diabéticas e doenças associadas ao envelhecimento, e, método para tratar um paciente diabético e para prevenir ou tratar doenças causadas por complicações associadas à diabetes e ao envelhecimento
ATE374781T1 (de)	2007-10-15	Derivate von genkwanin und sakuranetin, deren kosmetische und therapeutische verwendung, und verfahren zu deren herstellung
DE60125036T2 (de)	2007-06-21	Hydroxyformamidin-derivate und diese enthaltende medikamente
Bocci et al.	2004	Rational bases for using oxygen-ozonetherapy as a biological response modifier in sickle cell anemia and beta-thalassemia: a therapeutic perspective
CN102470129A (zh)	2012-05-23	作为药物使用的组合制剂
FI891155A0 (fi)	1989-03-10	Menetelmä terapeuttisesti käyttökelpoisten 4,5,6,7-tetrahydroisotiatsolo/4,5-c/pyridiini-johdannaisten ja niiden isomeerien ja happoadditiosuolojen valmistamiseksi
KR0148224B1 (ko)	1998-08-17	진양조성물
AU2004226547B2 (en)	2008-10-23	T-Type calcium channel blockers
ES2322538T3 (es)	2009-06-23	Inhibidores contra el aumento de la tension ocular causada por irradiacion con laseres, que contienen derivados de 1,4-dihidropiridina.
JP3154834B2 (ja)	2001-04-09	チロシナーゼ阻害剤
EP2228365A1 (de)	2010-09-15	Pharmazeutische Kombination aus 5-Fluorouracil und neuen wasserlöslichen 2,6-Dimethyl-1,4-Dihydropyridin-3,5-Dicarbonsäureesterähnlichen Verbindungen
CH666183A5 (it)	1988-07-15	Composizione farmaceutica ad azione protettiva cardiaca e metabolica sul metabolismo energetico muscolare.
JP2002363076A (ja)	2002-12-18	フマギロール誘導体を用いる腫瘍の治療方法
US20070112041A1 (en)	2007-05-17	Nicardipine injection composition
AU2005216862A1 (en)	2005-09-09	Compositions comprising prodrugs of proton pump inhibitors